Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 263

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 263
---
CLEP) Test Approval for its APOE Genotyping test from the New York State Department
of Health (NYSDOH). The approval allows DiamiR to offer its APOE Genotyping molecular testing in blood, buccal swab, saliva, and tissue,
through its CLIA certified, CAP accredited clinical laboratory by licensed healthcare providers in New York State and nationwide.

In May 2025, DiamiR entered
into a fee-for-service agreement to perform exploratory blood biomarker testing for a life sciences company developing therapeutic agent
for AD. DiamiR was compensated based on the number of samples tested and paid on achieving certain milestones related to the completion
of analytical work on a percentage of samples in the study. The study was pre-clinical/research in nature and was not part of an FDA submission.

In May 2025, DiamiR successfully
renewed its CT State and CLIA licenses after an inspection of its New Haven CT laboratory by State inspectors. These 2 licenses will expire
on June 15, 2026 and April 13, 2027, respectively.

In April 2025, DiamiR
began offering its microRNA biomarker testing services and updated its website to advertise this service to prospective biopharma customers.
DiamiR’s biomarker testing services are fee for service laboratory testing and are considered to be R&D work. As such, these
tests do not fall under LDT regulations specified by the FDA for commercial tests that are used for patient care and treatment decisions.

In April 2025, DiamiR
successfully passed its CAP inspection and its accreditation was renewed for an additional 2 years until April 13, 2027.

In April 2025 and June 2025,
DiamiR amended the convertible note with Kira Sheinerman, one of its founders and the Executive Director, such that the founder loaned
DiamiR additional $100,000 and $150,000, respectively.

Cyber Attack

DiamiR recently discovered
a cyber-attack and is still uncovering the full details of it. As of the date hereof, the basis of the attack is believed to be phishing.
As DiamiR learns more about the source of the attack and its implications, it will disclose such details in future amendments to this
proxy statement/prospectus.

<div align='center'>146</div>

Financial Operations Overview

Revenue

In 2010, DiamiR began the process